题目Title: Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera

共同第一作者Co-first author: Jie Hu (胡杰)、Xiao-yu Wei（魏晓宇）、Jin Xiang（向进）

摘要Abstract: 

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Spike protein that mediates coronavirus entry into host cells is a major target for COVID-19 vaccines and antibody therapeutics. However, multiple variants of SARS-CoV-2 have emerged, which may potentially compromise vaccine effectiveness. Using a pseudovirus-based assay, we evaluated SARS-CoV-2 cell entry mediated by the viral Spike B.1.617 and B.1.1.7 variants. We also compared the neutralization ability of monoclonal antibodies from convalescent sera and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that, compared to D614G and B.1.1.7 variants, B.1.617 shows enhanced viral entry and membrane fusion, as well as more resistant to antibody neutralization. These findings have important implications for understanding viral infectivity and for immunization policy against SARS-CoV-2 variants.

关键词Keywords:

SARS-CoV-2，Coronavirus， Mutation， Viral entry， Neutralizing antibodies， Vaccine， Immune escape

新冠病毒（2019-nCoV）；冠状病毒；突变/变异; 病毒侵入/入胞；中和抗体；疫苗；免疫逃逸

Hu J, Wei XY, Xiang J, Peng P, Xu FL, Wu K, Luo FY, Jin AS, Fang L, Liu BZ, Wang K, Tang N, Huang AL. Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera. Genes Dis. 2021 Dec 3;. doi: 10.1016/j.gendis.2021.11.007. PubMed PMID: 34877393; PubMed Central PMCID: PMC8639289.

全文链接 Full Length Article：https://doi.org/10.1016/j.gendis.2021.11.007